Neurogene Completes Dosing In Embolden Registrational Trial Of NGN-401, Investigational Gene Therapy Designed To Be One-Time Treatment For Rett Syndrome

Loading news article.

Neurogene Completes Dosing In Embolden Registrational Trial Of NGN-401, Investigational Gene Therapy Designed To Be One-Time Treatment For Rett Syndrome | WAPE

Neurogene Completes Dosing In Embolden Registrational Trial Of NGN-401, Investigational Gene Therapy Designed To Be One-Time Treatment For Rett Syndrome

Article summary

Related companies

Comments —